The ALMA Survey of Star Formation and Evolution in Massive Protoclusters with Blue Profiles (ASSEMBLE): Core Growth, Cluster Contraction, and Primordial Mass Segregation

The ALMA Survey of Star Formation and Evolution in Massive Protoclusters with Blue Profiles (ASSEMBLE) aims to investigate the process of mass assembly and its connection to high-mass star formation theories in protoclusters in a dynamic view. We observed 11 massive (Mclump>1000 Msun), luminous (Lbol>10,000 Lsun), and blue-profile (infall signature) clumps by ALMA with resolution of 2200-5500 au at 350 GHz (870 um) in continuum and line emission. 248 dense cores were identified, including 106 cores showing protostellar signatures and 142 prestellar core candidates. Compared to early-stage infrared dark clouds (IRDCs) by ASHES, the core mass and surface density within the ASSEMBLE clumps exhibited significant increment, suggesting concurrent core accretion during the evolution of the clumps. The maximum mass of prestellar cores was found to be 2 times larger than that in IRDCs, indicating evolved protoclusters have the potential to harbor massive prestellar cores. The mass relation between clumps and their most massive core (MMCs) is observed in ASSEMBLE but not in IRDCs, which is suggested to be regulated by multiscale mass accretion. The mass correlation between the core clusters and their MMCs has a steeper slope compared to that observed in stellar clusters, which can be due to fragmentation of the MMC and stellar multiplicity. We observe a decrease in core separation and an increase in central concentration as protoclusters evolve. We confirm primordial mass segregation in the ASSEMBLE protoclusters, possibly resulting from gravitational concentration and/or gas accretion.Comment: 37 pages, 13 figures, 5 tables; accepted for publication in ApJ

Interaction of SET domains with histones and nucleic acid structures in active chromatin

Changes in the normal program of gene expression are the basis for a number of human diseases. Epigenetic control of gene expression is programmed by chromatin modifications—the inheritable “histone code”—the major component of which is histone methylation. This chromatin methylation code of gene activity is created upon cell differentiation and is further controlled by the “SET” (methyltransferase) domain proteins which maintain this histone methylation pattern and preserve it through rounds of cell division. The molecular principles of epigenetic gene maintenance are essential for proper treatment and prevention of disorders and their complications. However, the principles of epigenetic gene programming are not resolved. Here we discuss some evidence of how the SET proteins determine the required states of target genes and maintain the required levels of their activity. We suggest that, along with other recognition pathways, SET domains can directly recognize the nucleosome and nucleic acids intermediates that are specific for active chromatin regions

Liquid biopsies come of age: towards implementation of circulating tumour DNA

Improvements in genomic and molecular methods are expanding the range of potential applications for circulating tumour DNA (ctDNA), both in a research setting and as a ‘liquid biopsy’ for cancer management. Proof-of-principle studies have demonstrated the translational potential of ctDNA for prognostication, molecular profiling and monitoring. The field is now in an exciting transitional period in which ctDNA analysis is beginning to be applied clinically, although there is still much to learn about the biology of cell-free DNA. This is an opportune time to appraise potential approaches to ctDNA analysis, and to consider their applications in personalized oncology and in cancer research.We would like to acknowledge the support of The University of Cambridge, Cancer Research UK (grant numbers A11906, A20240, A15601) (to N.R., J.D.B.), the European Research Council under the European Union's Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement n. 337905 (to N.R.), the Cambridge Experimental Cancer Medicine Centre, and Hutchison Whampoa Limited (to N.R.), AstraZeneca (to R.B., S.P.), the Cambridge Experimental Cancer Medicine Centre (ECMC) (to R.B., S.P.), and NIHR Biomedical Research Centre (BRC) (to R.B., S.P.). J.G.C. acknowledges clinical fellowship support from SEOM

Search for dark matter candidates and large extra dimensions in events with a jet and missing transverse momentum with the ATLAS detector

Open Access, Copyright CERN, for the benefit of the ATLAS collaboration. This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution and reproduction in any medium, provided the original author(s) and source are credited